Business Context and Reporting Period
This Form 8-K Current Report was filed by Spero Therapeutics, Inc. on February 28, 2020. The filing primarily addresses a material modification to the rights of security holders and amendments to the Articles of Incorporation related to a rights offering announced on February 11, 2020.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure changes rather than operational financial performance.
Material Changes
The Company designated 3,333 shares of authorized and unissued preferred stock as Series C Convertible Preferred Stock. Key terms include:
- Conversion: Each share converts into 1,000 shares of Common Stock, subject to a 9.99% beneficial ownership limitation.
- Liquidation Preference: Holders receive $0.001 per share prior to Common Stock distributions, ranking pari passu with Series A and Series B Preferred Stock.
- Voting Rights: Generally no voting rights, except for amendments to the Series C terms.
- Dividends: Entitled to receive dividends payable to Common Stock holders.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the structural terms of the new security. The Series C Preferred Stock was created in connection with a rights offering to existing holders of Common Stock, Series A, and Series B Preferred Stock.
Investor Verification Checklist
- Review the Certificate of Designation (Exhibit 3.1) for complete terms of the Series C Preferred Stock.
- Verify the impact of the 9.99% conversion limitation on potential dilution.
- Confirm the status of the rights offering prospectus supplement filed on February 11, 2020.
- Check subsequent filings for the actual issuance volume of Series C Preferred Stock.